$2.41
-0.21 (-8.02%)
Open$2.57
Previous Close$2.62
Day High$2.60
Day Low$2.39
52W High$3.82
52W Low$1.09
Volume—
Avg Volume2.06M
Market Cap255.65M
P/E Ratio—
EPS$-1.36
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+1,528.2% upside
Current
$2.41
$2.41
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.31M | 40.31M | 17.10M |
| Net Income | -123,592,517 | -105,986,913 | 3.03M |
| Profit Margin | -292.1% | -277.5% | 17.7% |
| EBITDA | -133,330,819 | -120,690,117 | 5.37M |
| Free Cash Flow | — | — | 3.54M |
| Rev Growth | +5.0% | +5.0% | +6.2% |
| Debt/Equity | — | — | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |